Lundbeck peddles meds to Recordati for $100M; Amarin hits another FDA delay on Vascepa;

@FiercePharma: AstraZeneca beats back would-be Crestor copycats. Report | Follow @FiercePharma

> Denmark's Lundbeck said it would sell off a handful of products to Italy's Recordati for $80 million up front and a possible $20 million in additional payments. Report

> The FDA once again delayed its decision on Amarin's ($AMRN) market exclusivity for its blood-lipid drug Vascepa. Report

> Europe's drug-review committee has recommended against approval of Vanda Pharmaceuticals' ($VNDA) antipsychotic drug Fanaptum. Report

> Prominent pediatricians and public health experts warn that banning the vaccine preservative thimerosal would interfere with immunization campaigns in developing countries. Report (sub. req.)

> Mayne Pharma is raising $19 million to fund the acquisition of GlaxoSmithKline's ($GSK) morphine-based pain drug Kapanol. Report (sub. req.)

Medical Device News

 @FierceMedDev: Malaysia is working hard to diversify its med device manufacturing base. International competition is increasing. News | Follow @FierceMedDev

@MarkHFierce: Barron's sees J&J poised for major growth, but NOT through its med device business. More | Follow @MarkHFierce

 @DamianFierce: Quintiles is handling recruitment and "clinical services" for AstraZeneca's novel depression drug. Story | Follow @DamianFierce

> Orthofix resolves Medicare kickback case. News

> Amarantus licenses Alzheimer's blood Dx. Story

> Bioresorbable stents hit India, but most patients can't afford them. Article

Biotech News

 @FierceBiotech: Baxter joins Big Pharma funds on $38M B round for Naurex antidepression R&D. Article | Follow @FierceBiotech

@JohnCFierce: Troubled Intercell (bought Iomai) throws in the towel, signs off on merger deal with Vivalis. More | Follow @JohnCFierce

@RyanMFierce: Dang. Another biotech deal this busy am. Naurex nails down $38M B round led by Baxter for depression candidate. Release | Follow @RyanMFierce

> Tranzyme takes a beating after scuttling another drug study. Report

> Apple Tree inks $305M drug deal to back biotech portfolio game plan. News

> Phenex grabs $135M discovery deal with J&J. Item

Biotech IT News

> How lessons from iPhone's Siri aid biological exploration. Story

> GlaxoSmithKline dials up Vodafone for mobile tech alliance. Article

> Russian billionaire backs 23andMe in $50M round. News

> Could computers predict the next big Alzheimer's drug? Report

CRO News

> Patheon closes $255M Banner deal. Item

> Charles River projects a modest 2013, slides on the Street. Story

> Catalent inks biosimilar deal with Japanese CMO. Article

> Quintiles recruiting for AstraZeneca's novel depression drug. News

> Warnex closes bioanalytics sale, exits CRO biz. Report

And Finally... A longtime proponent of opioid painkillers is backpedaling on early recommendations as new research suggests a higher risk of addiction than previously thought. Report (sub. req.)

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.